2025 AMA Research Challenge – Member Premier Access

October 22, 2025

Virtual only, United States

Would you like to see your presentation here, made available to a global audience of researchers?
Add your own presentation or have us affordably record your next conference.

CD38 is an ideal molecular imaging target for multiple myeloma. It is relatively specific for plasma cells and the target of first line therapeutic antibodies, Daratumumab and Isatuximab. Here, we have added a lipid tail to a peptide-based radiotracer that targets CD38 in order to template self-assembly into a polyvalent nanofiber with excellent affinity for CD38. In vitro, the nanofiber outcompetes the monomer for uptake by CD38+ MOLP2 cells. Additionally, these nanofibers can be used to encapsulate and deliver small molecule therapeutics.

Next from 2025 AMA Research Challenge – Member Premier Access

Primary Pulmonary Follicular Lymphoma Presenting with Bilateral Pleural Effusion: A 
Rare Case Report

Primary Pulmonary Follicular Lymphoma Presenting with Bilateral Pleural Effusion: A Rare Case Report

2025 AMA Research Challenge – Member Premier Access

Sanathanan Neelakantan Ramaswamy

22 October 2025